TY - JOUR T1 - Initial Activation Status of the Antioxidant Response Determines Sensitivity to Carboplatin/Paclitaxel Treatment of Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 4723 LP - 4728 VL - 32 IS - 11 AU - DANIEL G. PONS AU - JORGE SASTRE-SERRA AU - MERCEDES NADAL-SERRANO AU - AINA OLIVER AU - MAGDALENA GARCÍA-BONAFÉ AU - ISABEL BOVER AU - PILAR ROCA AU - JORDI OLIVER Y1 - 2012/11/01 UR - http://ar.iiarjournals.org/content/32/11/4723.abstract N2 - Background/Aim: Ovarian carcinoma is the main cause of gynecological cancer related deaths. The aim of this study was to determine the activation status of the antioxidant response in samples of ovarian serous carcinoma from paraffin-embedded biopsies and compare them with the response of patients to carboplatin-paclitaxel treatment. Materials and Methods: Estrogen receptor alpha (ERα), antioxidant enzymes, and uncoupling protein (UCP) levels were analyzed by western blotting and the presence of estrogen receptor beta (ERβ) was investigated by immunohistochemistry (IHC). Results: Lower levels of ERα, antioxidant enzymes and UCPs were found in patients resistant to treatment in comparison to the carboplatin/paclitaxel-sensitive ones; IHC revealed a greater presence of ERβ in sensitive patients. Conclusion: These results indicate that patients resistant to treatment have a lower level of antioxidant response activation compared to sensitive patients, fact which may be related to the efficacy of this treatment. ER -